Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations PFL-002/VERT-002 is …
Health
-
Uncategorized
-
Uncategorized
Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia
by PRNW Agencyby PRNW AgencySINGAPORE , Oct. 21, 2024 /PRNewswire/ — Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our …
-
Uncategorized
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara®
by PRNW Agencyby PRNW AgencyAHMEDABAD, India , Oct. 19, 2024 /PRNewswire/ — Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for range …
-
Uncategorized
Medeze Group Awarded Frost & Sullivan’s 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions
by PRNW Agencyby PRNW AgencyMedeze Group (Medeze) specializes in cutting-edge stem cell banking services, leveraging advanced cryopreservation techniques and pioneering therapies to enhance longevity and health outcomes. SAN ANTONIO , Oct. 18, 2024 /PRNewswire/ …
-
A Leading Producer of Monoclonal Antibodies LEBANON, N.H. , Oct. 17, 2024 /PRNewswire/ — Bio X Cell, LLC (“BXC” or the “Company”), the world’s leading producer of monoclonal antibodies for …
-
Uncategorized
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts
by PRNW Agencyby PRNW AgencyCurrent mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass. , Oct. 9, 2024 /PRNewswire/ — Today, the INTREPID Alliance, a consortium of …
-
Uncategorized
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
by PRNW Agencyby PRNW AgencyPFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor (“EGFR”) inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON …
-
Uncategorized
Veritas Genetic participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients
by PRNW Agencyby PRNW AgencyThe study, conducted in collaboration with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata and Tor Vergata University Hospital, underscores the relevance of polygenic risk scores …
-
Uncategorized
Axtria Recognized for Excellence in AI with a Minsky Award at Cypher 2024
by PRNW Agencyby PRNW AgencyAxtria’s GenAI innovations were recognized at India’s most prestigious AI awards for driving operational excellence and transforming solutions for life sciences companies. BANGALORE, India, Sept. 27, 2024 /PRNewswire/ — Axtria Inc., …
-
Uncategorized
25 Years of Innovation and Excellence: Alma Celebrates Silver Anniversary at the Seventh Alma Academy Event in Thailand
by PRNW Agencyby PRNW AgencyCAESAREA, Israel, Sept. 27, 2024 /PRNewswire/ — Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has announced the global launch of its …